Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. [electronic resource]
Producer: 20180521Description: 499-506 p. digitalISSN:- 1873-7560
- 5-alpha Reductase Inhibitors -- adverse effects
- Aged
- Animals
- Biomarkers, Tumor -- genetics
- Chemotherapy, Adjuvant
- Clinical Decision-Making
- DNA Mutational Analysis
- Dutasteride -- adverse effects
- Finasteride -- adverse effects
- Homeodomain Proteins -- genetics
- Humans
- Male
- Mice, Knockout
- Middle Aged
- Mutation
- Neoadjuvant Therapy
- Neoplasm Staging
- Patient Selection
- Precision Medicine
- Predictive Value of Tests
- Prostatectomy
- Prostatic Intraepithelial Neoplasia -- drug therapy
- Prostatic Neoplasms -- drug therapy
- Retrospective Studies
- Time Factors
- Transcription Factors -- genetics
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.